Quantcast

Latest Prothrombin time Stories

2014-06-11 08:32:01

LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coagulation Diagnostic Testing Marketshttp://www.reportbuyer.com/pharma_healthcare/diagnostics/coagulation_diagnostic_testing_markets_1.html Coagulation testing, which encompasses both laboratory and point of care (POC) testing, will continue to be one of the most important segments of the in vitro diagnostics market for the foreseeable future. Many of the new models of laboratory...

2014-05-12 11:38:13

Intermountain Medical Center Study included 2,600 AFib patients A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City has found that atrial fibrillation patients who are on blood thinning medications are at higher risk of developing dementia if their doses are not in the optimal recommended range. The study of more than 2,600 AFib patients found they are significantly more likely to develop dementia when using medicines to prevent blood...

2014-05-06 08:35:23

Healthcare Professionals Should Stop Using Strips WALTHAM, Mass., May 6, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR) has initiated a voluntary Class 1 recall in the U.S. of the Alere INRatio2 PT/INR Professional Test Strips (PN 99008G2). This action is a result of complaints of patients who had a therapeutic or near therapeutic INR with the Alere INRatio2 PT/INR Professional Test Strip but a significantly higher INR (outside of therapeutic range) when performed by a central laboratory. Alere...

2014-04-29 08:34:35

Recently Released ACC/AHA Practice Guidelines Reinforce Unmet Need MENLO PARK, Calif., April 29, 2014 /PRNewswire/ -- Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin. Tecarfarin is positioned to be the only oral anticoagulant (OAC) therapy for patients with prosthetic heart valves (PHV) specifically identified in the label. In addition, the...

2014-03-24 08:26:49

Results Show Highest Rate of Control Ever Observed with Warfarin in Real-world Setting, Surpassing Thresholds for Cost-Effectiveness of Newer Agents Identified in Five Recent Independent Studies WALTHAM, Mass., March 24, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR) today announced the publication of the largest-ever study of warfarin patient self-testing, which demonstrated that weekly International Normalized Ratio (INR) testing significantly improves control of warfarin, as measured...

2014-03-04 16:25:59

Results Published in Nursing 2014 Show that Self-testing Protocol Reduced Out-of-Range Coagulation Test Results and Need for Clinic Follow-up WALTHAM, Mass., March 4, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, today announced the results of a study demonstrating that at-home coagulation testing among...

2014-02-11 12:27:14

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/h477tv/coagulation ) has announced the addition of the "Concise Analysis on the International Coagulation Self-Testing Devices, Markets, Players and Prospects" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ability of patients to self-monitor is deemed to be a critical tool in reducing the pathological effects of difficult-to-control disease...

2014-02-04 20:22:36

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxcwmp/coagulation) has announced the addition of the "Concise Analysis of the International Coagulation Diagnostic Testing Markets" [http://www.researchandmarkets.com/research/qxcwmp/coagulation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Coagulation testing, which encompasses both laboratory and point of care...

2014-02-04 12:26:39

The Quest Diagnostics Health Trends(TM) study of 2.7 million test results is the largest to examine warfarin treatment in patients with atrial fibrillation (Afib) treated in primary care and other non-hospital care settings in the United States MADISON, N.J., Feb. 4, 2014 /PRNewswire/ -- Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy,...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.